Earnings Call Summary | Rockwell Medical(RMTI.US) Q1 2024 Earnings Conference
Earnings Call Summary | Rockwell Medical(RMTI.US) Q1 2024 Earnings Conference
The following is a summary of the Rockwell Medical, Inc. (RMTI) Q1 2024 Earnings Call Transcript:
以下是羅克韋爾醫療公司（RMTI）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Rockwell Medical reported Q1 2024 net sales of $22.7 million, a record for quarterly concentrate product revenue, representing a 15% increase over Q1 2023 results.
Gross profit for Q1 2024 was $3.1 million, an 18% increase over the same period in 2023.
The company revised its guidance for 2024, now expecting net sales for 2024 between $90 million and $94 million, and a gross profit between $13 million and $15 million.
羅克韋爾醫療公佈的2024年第一季度淨銷售額爲2,270萬美元，創下了濃縮產品季度收入的紀錄，比2023年第一季度的業績增長了15％。
2024年第一季度的毛利爲310萬美元，比2023年同期增長18％。
該公司修訂了2024年的指導方針，現在預計2024年的淨銷售額在9000萬美元至9400萬美元之間，毛利潤在1300萬至1500萬美元之間。
Business Progress:
業務進展：
After the Evoqua's hemodialysis concentrates business acquisition, Rockwell Medical adjusted its product pricing and saw an increase in customer interest from various health systems and dialysis centers both nationally and internationally.
They have also secured several expanded agreements both domestically and internationally and expect to achieve a gross margin of 20% by 2025 and beyond 25% by 2026.
收購Evoqua的血液透析濃縮液業務後，羅克韋爾醫療調整了產品定價，國內外各種醫療系統和透析中心的客戶興趣有所增加。
他們還簽訂了幾項國內外擴大的協議，預計到2025年毛利率將達到20％，到2026年將超過25％。
More details: Rockwell Medical IR
更多詳情： 羅克韋爾醫療紅外線
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由 AI 生成。無法完全保證內容的準確性。欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。